盐酸丁丙诺啡(Buprenorphine Hydrochloride) - 药物靶点：κ opioid receptor x μ opioid receptor_在研适应症：阿片滥用，慢性疼痛，疼痛_专利_临床

概要

基本信息

简介盐酸丁丙诺啡（Buprenorphine Hydrochloride）是于1981年12月29日在美国获批上市，由Indivior公司生产。该药物的适应症为缓解疼痛，且疼痛程度足以需要使用阿片类镇痛剂，且其他治疗方法不足以缓解疼痛。其机制是通过作为μ-阿片受体的部分激动剂和κ-阿片受体的拮抗剂来发挥作用。在体外研究中，丁丙诺啡的一个特性是从受体中解离的速度非常缓慢。这可能是导致其作用时间比吗啡长、被阿片类拮抗剂逆转的不可预测性，以及其表现出低水平身体依赖性的原因。

药物类型

小分子化药

别名

BUP-XR、Buprenorphine hydrochloride (JP17/USP)、Buprenorphine Transdermal Patch

+ [38]

靶点

κ opioid receptor x μ opioid receptor

作用方式

拮抗剂、激动剂

作用机制

κ opioid receptor拮抗剂(κ-阿片受体拮抗剂)、μ opioid receptor激动剂(μ-阿片受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.Indivior, Inc.RB Pharmaceuticals Ltd.

+ [7]

非在研机构

Purdue Pharma LP北京大学中国药物依赖性研究所

Braeburn, Inc.

+ [11]

权益机构

Purdue Pharma LPL. MOLTENI & C. DEI FRATELLI ALITTI - SOCIETA DI ESERCIZIO - S.P.A.Sandoz, Inc.

+ [9]

最高研发阶段批准上市

首次获批日期

美国 (1981-12-29),

疼痛

最高研发阶段(中国)撤市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C29H42ClNO4

InChIKeyUAIXRPCCYXNJMQ-RZIPZOSSSA-N

CAS号53152-21-9

关联

322

项与盐酸丁丙诺啡相关的临床试验

ACTRN12625000385448

/ Not yet recruiting临床2期

A Phase 2, Open-Label Trial Assessing the Feasibility of Direct Transfer from Methadone to CAM2038 (Buprenorphine) in Patients with Opioid Dependence

开始日期2025-06-18

申办/合作机构-

NCT06379984

/ Recruiting临床2期IIT

Rapid Outpatient Low-dose Initiation of Buprenorphine for Individuals With OUD Using Fentanyl

The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test.
Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpatient low-dose initiation (ROLDI).
For standard initiation, participants will be instructed to arrive to the unit with at least 8 hours since last fentanyl use. Once they have at least moderately severe opioid withdrawal (Clinical Opiate Withdrawal Scale [COWS] 11 or higher), participants will receive 2 mg, 2 mg, 4 mg, and then 8 mg sublingual buprenorphine, with doses every 2 hours. They will then continue 8 mg twice daily (or up to three times daily). This is the current standard of care.
For ROLDI, participants will not be required to have a period abstinence, they will have no or minimal withdrawal (COWS 4 or less) when starting buprenorphine, and participants will take 0.5 mg, 0.5 mg, 1 mg, 1 mg, 1 mg, and then 4 mg sublingual buprenorphine with dosing every two hours. They will then continue 8mg twice daily (or up to three times daily).
The main aim of this clinical trial is to assess whether ROLDI is safe, feasible, acceptable to patients, and worthwhile to study in a larger trial. The secondary aim is to describe fentanyl and norfentanyl pharmacokinetics (that is to say, fentanyl and norfentanyl concentration in blood and urine) during early abstinence to understand why some people using fentanyl develop precipitated withdrawal with standard initiation.

开始日期2025-05-08

申办/合作机构

University of Pennsylvania

[+1]

CTRI/2025/04/084623

/ Not yet recruiting临床2/3期IIT

A Prospective study to compare epidural buprenorphine versus epidural tramadol for post operative analgesia in lower limb orthopedic replacement surgeries. - nil

开始日期2025-04-21

申办/合作机构-

100 项与盐酸丁丙诺啡相关的临床结果

登录后查看更多信息

100 项与盐酸丁丙诺啡相关的转化医学

登录后查看更多信息

100 项与盐酸丁丙诺啡相关的专利（医药）

登录后查看更多信息

5,382

项与盐酸丁丙诺啡相关的文献（医药）

2025-10-01·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Effects of re-enter water on antioxidant, immune, intestinal flora and metabolome of Chinese mitten crab (Eriocheir sinensis) after high temperature air exposure

Article

作者: Wang, Shihui ; Luo, Liang ; Yang, Yuhong ; Zhao, Zhigang ; Li, Zhiqiang ; Guo, Kun ; Deng, Xiangyi ; Zhang, Rui

Both air exposure stress and heat stress can cause stress responses of Eriocheir sinensis and affect its normal life activities. The objective of this research was to investigate the impact of re-enter water treatment on immunoenzyme activity, immune-related gene expression, hemolymph parameters, intestinal microbiota composition, and metabolomic profiles in Eriocheir sinensis after being subjected to high-temperature air exposure. The findings indicated that the re-enter water effectively mitigated the negative impacts of high-temperature air exposure on both antioxidant and immune capacities. Following treatment with high-temperature air, levels of acid phosphatase (ACP), alkaline phosphatase (AKP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly elevated compared to their baseline values (P < 0.05), followed by a decline as re-enter water started with recovery to baseline levels detected at 24 h after re-enter water. Additionally, the levels of heat shock proteins HSP90 and HSP70 exhibited a notable rise after being subjected to high-temperature air. Nevertheless, after 24 h of soaking treatment, these levels reverted to values similar to those recorded initially. However, after re-enter water treatment, the changes in intestinal microbial composition and metabolic level caused by high temperature air exposure were not effectively improved. The analysis of intestinal microbiota revealed that the relative abundance of Bacteroidetes in the recovery group was significantly lower compared to the initial group, whereas the relative abundances of Proteobacteria and Firmicutes were found to be higher than those in the initial group. Concurrently, metabolomics analysis indicated a significant increase in palmitic acid metabolism levels within the high-temperature air group (P < 0.05), while glycine content showed a notable decrease (P < 0.05), and the metabolic changes caused by high temperature air exposure was still not fully recovered after re-enter water.

2025-09-01·WATER RESEARCH

Estimating the consumption of prescription opioids through wastewater analysis: The patterns of use in Italy

Article

作者: de Voogt, Pim ; Béen, Frederic ; van Nuijs, Alexander L N ; Castiglioni, Sara ; Zuccato, Ettore ; Corli, Oscar ; Hernández, Félix ; Matias, João ; Bijlsma, Lubertus ; Boogaerts, Tim ; Salgueiro-Gonzalez, Noelia ; Kasprzyk-Hordern, Barbara

Prescription opioids have recently experienced a diversion of use in several countries causing a huge number of overdoses due to their high potency. The aim of this study was to develop a wastewater-based epidemiology (WBE) approach to assess the use of prescription opioids and evaluate the compliance to prescriptions to highlight the potential misuse of these substances in Italy. The most prescribed opioids have been selected and validated as WBE biomarkers and a nation-wide study has been conducted over a three-year period (2020-2022). Wastewater (WW) samples were collected as 24-hour composite samples in eight Italian cities and parent substances or metabolites were quantified using validated analytical methods based on liquid chromatography - tandem mass spectrometry (LC-MS/MS). Daily loads have been normalized to therapeutic doses to obtain a real figure of use that showed higher use of tapentadol and morphine compared to oxycodone and fentanyl. Back-calculation of consumption estimates was done by using the most reliable WBE biomarkers and were compared with prescription data. Spatial and temporal differences were found and highlighted a lower use in the south compared to the north and the center of Italy. Data comparison with prescriptions gave results in the same range indicating that the use of these substances in Italy seems to be predominantly from prescription for therapeutic purposes. This study highlighted the suitability of WBE to investigate the potential non-medical use of prescription pharmaceuticals in a population, providing relevant information for supporting public health emergencies and policies.

2025-09-01·Drug and alcohol dependence reports

Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients

Article

作者: Gu, Yifan ; Wheeler, Ann ; Dunne, Robert ; DeKoven, Mitch ; Munnangi, Swapna ; Mullen, William ; Gaiazov, Sabrina

Objective:

Identify factors associated with 6-month emergency room (ER) outcomes in patients with opioid use disorder (OUD) and/or treated with buprenorphine (extended-release [BUP-XR] or transmucosal [BUP-TM]). Compare baseline characteristics and 6-month ER visits and healthcare resource utilization (HCRU) across treatment groups.

Methods:

Patient claims data from September 2017- March 2022 were analyzed for patients diagnosed with OUD and/or treated with buprenorphine. Adjusted logistic regression models were used to identify factors associated with ER visits 6-months post-index.

Results:

543 patients initiating BUP-XR, 52,569 BUP-TM and 57,125 patients with OUD diagnosis but no-medications for opioid use disorder (MOUD) were identified.Patients who received BUP-XR (OR: 0.43, 95 % CI: 0.36-0.53) or BUP-TM (OR: 0.78; CI: 0.76-0.81) had lower odds for an all-cause post-index ER visit compared to those with no MOUD treatment.Patients with later index years or those who had an opioid overdose ER visit in the baseline period had higher odds of post-index all-cause and opioid overdose ER visits.1.2 % in BUP-TM cohort and 1 % in the no MOUD cohort had an opioid overdose ER visit, compared to 0 % in the BUP-XR cohort. The BUP-XR cohort had lower rates of inpatient stays, ER visits, and outpatient physician office visits compared to the BUP-TM and no MOUD cohorts but incurred higher pharmacy costs.

Conclusions:

This study found that any buprenorphine treatment, particularly BUP-XR, was associated with lower odds of all-cause ER visits compared to patients with no MOUD, and highlighted potential risk factors that could help reduce the demand on ER services.

337

项与盐酸丁丙诺啡相关的新闻（医药）

2025-05-12

·GlobeNewswire-Health Care

Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment

DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is proud to announce the acquisition of Comprehensive Behavioral Health Center (CBHC), a respected Opioid Treatment Program (OTP) provider with clinics in Denver and Lakewood, Colorado. This strategic partnership marks a pivotal step in advancing Porch Light Health’s mission to broaden access to high-quality, patient-centered care for individuals living with opioid use disorder through evidence-based treatment solutions. By adding OTP services, Porch Light Health will now offer the full spectrum of MAT options—including buprenorphine, methadone and naltrexone—ensuring that patients receive the most appropriate treatment for their unique needs. “In combining our strengths with CBHC, we are deepening our impact to create an even more integrated care environment that prioritizes access, innovation and recovery for every individual seeking treatment, ” said Doug Weiss, MBA, Chief Executive Officer at Porch Light Health. While day-to-day operations will remain largely unchanged, the collaboration presents expanded opportunities to experience life beyond addiction. “This is a significant step forward in breaking down long-standing barriers in addiction medicine,” said Joy Mercer, BA and CAS, Program Director at CBHC. “This comprehensive approach is a win-win. We reaffirm that there is no ‘one-size-fits-all’ approach to recovery. Through Porch Light Health, our patients will now have access to additional services, including psychiatric medicine management, behavioral health care, infectious disease treatment and more.” Together, Porch Light Health and CBHC will continue to challenge stigma, innovate care delivery and empower individuals on the path to recovery. About Porch Light Health Porch Light Health’s mission (formerly Front Range Clinic), is to provide low-barrier, high-access, quality medical addiction treatment to those affected by substance use disorders and related medical conditions. Porch Light Health offers comprehensive outpatient addiction medicine treatment service for alcohol and drug use disorders, including Opioids, Stimulants and Sedatives, as well as nicotine and cannabis use. In addition to evidence-based medical treatment, PLH offers psychiatry and therapy services, including treatment of infectious disease and other comorbidities. Media Contact:Dayle Cedars303-907-3698daylecedars@gmail.com https://porchlighthealth.com

并购

2025-05-12

·EINPresswire

Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment

DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is proud to announce the acquisition of Comprehensive Behavioral Health Center (CBHC), a respected Opioid Treatment Program (OTP) provider with clinics in Denver and Lakewood, Colorado. This strategic partnership marks a pivotal step in advancing Porch Light Health’s mission to broaden access to high-quality, patient-centered care for individuals living with opioid use disorder through evidence-based treatment solutions. By adding OTP services, Porch Light Health will now offer the full spectrum of MAT options—including buprenorphine, methadone and naltrexone—ensuring that patients receive the most appropriate treatment for their unique needs. “In combining our strengths with CBHC, we are deepening our impact to create an even more integrated care environment that prioritizes access, innovation and recovery for every individual seeking treatment, ” said Doug Weiss, MBA, Chief Executive Officer at Porch Light Health. While day-to-day operations will remain largely unchanged, the collaboration presents expanded opportunities to experience life beyond addiction. “This is a significant step forward in breaking down long-standing barriers in addiction medicine,” said Joy Mercer, BA and CAS, Program Director at CBHC. “This comprehensive approach is a win-win. We reaffirm that there is no ‘one-size-fits-all’ approach to recovery. Through Porch Light Health, our patients will now have access to additional services, including psychiatric medicine management, behavioral health care, infectious disease treatment and more.” Together, Porch Light Health and CBHC will continue to challenge stigma, innovate care delivery and empower individuals on the path to recovery. About Porch Light Health Porch Light Health’s mission (formerly Front Range Clinic), is to provide low-barrier, high-access, quality medical addiction treatment to those affected by substance use disorders and related medical conditions. Porch Light Health offers comprehensive outpatient addiction medicine treatment service for alcohol and drug use disorders, including Opioids, Stimulants and Sedatives, as well as nicotine and cannabis use. In addition to evidence-based medical treatment, PLH offers psychiatry and therapy services, including treatment of infectious disease and other comorbidities. Media Contact: Dayle Cedars 303-907-3698 daylecedars@gmail.com https://porchlighthealth.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

并购

2025-04-14

·药融圈

老将重组收购：踏出疼痛舒适区，拓展医药多元版图

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。2024年9月3日，Collegium Pharmaceutical宣布完成对Ironshore Therapeutics的收购，此次交易Collegium Pharmaceutical不仅获得了Jornay，还将其业务扩展到了疼痛治疗以外的领域，并通过ADHD（注意力缺陷多动障碍，俗称多动症）市场在神经精神科领域建立商业地位。Jornay是一种含有盐酸哌甲酯的中枢神经系统兴奋剂处方药，2018年8月获得FDA批准用于治疗6岁及以上人群的ADHD，是目前唯一获得FDA批准的夜间给药兴奋剂药物。2024年度，Jornay PM（Jornay）销售额为3720万美元，预计2025年净收入会超过1.35亿美元。Collegium产品净收入为6.314亿美元，与上年同期相比增加了6460万美元。其他产品中，Belbuca收入增加了2920万美元，Xtampza ER收入增加了1400万美元，Nucynta产品收入减少了1430万美元，Symproic收入减少了140万美元。预计公司在2025年的净产品收入将在7.35~7.5亿美元之间，调整后EBITDA预计增长超过10%。截止2025年3月13日，Collegium Pharmaceutical公司总市值为9.16亿美元，约合人民币66.3亿元。发稿前市值为8.45亿美元。踏出舒适区的何许司也Collegium Pharmaceutical于2002年4月在特拉华州注册成立，随后，为了应对市场环境变化、优化业务结构和提升竞争力，公司2014年7月在弗吉尼亚州重组，2015年，公司上市并筹集了6000多万美元的总收益。上市当年，公司完成了关键的临床试验，FDA的麻醉和镇痛产品咨询委员会以及药物安全和风险管理咨询委员会一致投票支持批准Xtampza ER用于治疗严重疼痛，并于11月确认了该建议。此后，公司通过收购BioDelivery Sciences International等企业，不断扩大其产品组合，涵盖了更多的疼痛管理产品。来源：摩熵医药数据pharma.bcpmdata.com（原药融云数据）：融资信息当前，公司的主要业务位于马萨诸塞州斯托顿，旨在打造一家领先的多元化生物制药公司，在美国开发、许可并收购了用于治疗中度至重度疼痛和ADHD的差异化产品组合，包括Jornay、Belbuca、Xtampza ER（羟考酮缓释）、Nucynta产品（他喷他多，Nucynta ER和Nucynta IR）和Symproic（纳地美定，Naldemedine）。疼痛领域：开发收购不停2022年3月，Collegium Pharmaceutical收购了BioDelivery Sciences International（BDSI），这是一家专业制药公司，致力于为患有严重和使人衰弱的慢性病患者提供创新疗法。在完成对BDSI的收购后，公司获得了Belbuca和Symproic。其中，Belbuca是一种含有丁丙诺啡的口腔黏膜贴剂，于2015年10月获得FDA批准，用于治疗严重和持续的疼痛，这些疼痛需要延长治疗并每天服用阿片类镇痛药且替代方案不充分。Symproic用于治疗阿片类药物引起的便秘，最初由日本盐野义制药公司开发，于2017年3月获得FDA批准，2019年，BDSI从盐野义获得在美国的独家授权。该产品通过阻断肠道中的阿片受体，减轻阿片类药物对肠道蠕动的抑制作用，从而缓解便秘症状，其独特之处在于它不会穿过血脑屏障，因此不会影响阿片类药物的镇痛效果。Xtampza ER是一种抗滥用、缓释型的羟考酮口服制剂，主要用于治疗严重到需要每日24小时、长期阿片类药物治疗且替代治疗方案不足的疼痛。采用Collegium Pharmaceutical的专有技术平台DETERx配制而成，该平台提供缓释输送，旨在阻止滥用和误用。2016年4月获得FDA批准。Nucynta是一种用于治疗中度至重度疼痛的阿片类镇痛药物，主要成分是他喷他多，包括速释（NucyntaIR）和缓释（Nucynta ER）两种剂型。最初由强生旗下的杨森制药研发；Depomed以10.5亿美元收购了Nucynta在美国的商业化权利；随后Assertio Therapeutics收购了Depomed；2020年2月，Collegium Pharmaceutical宣布从Assertio Therapeutics完成了对Nucynta的收购。市场机遇：健康浪潮下的“新蓝海”1. 多维度的市场角逐Collegium Pharmaceutical所在行业技术发展快速、竞争激烈，同一赛道包括大型跨国公司、生物技术公司和其他研究机构，但主要竞争还是来自仿制药阿片类药物和兴奋剂市场，包括长效/缓释和速释阿片类药物。Belbuca、Xtampza ER和Nucynta与口服阿片类药物、透皮阿片类药物、局部麻醉贴剂以及可用于输注阿片类药物和局部麻醉剂的植入式和外部输液泵竞争。Jornay在市场上面临着来自其他已经上市的、品牌化的以及仿制药的同类产品竞争，这些竞争产品的主要成分是哌醋乙酯（常用于治疗ADHD的中枢神经系统兴奋剂）。公司目前正在积极与各类组织开展合作，以实现产品许可和技术开发的机会。通过与其他制药公司或科研机构的合作，能够充分利用各方的资源和优势，加速产品的研发进程，提高研发效率。当然，并购在公司的发展历程中更是起到了重要作用。通过收购一系列公司，不仅使公司快速获得成熟的产品和技术，还帮助公司拓展了业务领域，实现了多元化发展，增强了公司在制药市场中的竞争力。2. 疼痛与神经精神市场双驱动首先，随着社会的发展和人们对健康关注度的提高，对于疼痛管理和神经精神疾病治疗的需求不断增长。疼痛管理方面，慢性疼痛患者数量的增加以及对安全有效的镇痛药物的需求，为Collegium Pharmaceutical的产品提供了广阔的市场空间；在神经精神病学领域，ADHD等疾病的诊断率逐渐提高，患者对治疗药物的需求也在增加。公司可以抓住这些市场需求增长的机遇，进一步扩大市场份额，推动业务发展。另外，科技的不断进步为制药行业带来了新的技术创新机遇。例如，新的药物递送技术、基因编辑技术等的发展，为Collegium Pharmaceutical研发更高效、更安全的药物提供了可能性。公司可以加大在技术创新方面的投入，利用这些新技术改进现有产品或开发新产品，提升公司的核心竞争力。通过与科研机构合作或内部研发突破，公司有望在技术创新的推动下，实现业务的跨越式发展。参考：NMPA/CDE；摩熵医药数据库，https://pharma.bcpmdata.com/；FDA/EMA/PMDA；相关公司公开披露（除标注外，正文图片均来自企业官网）；https://www.collegiumpharma.com/；https://ir.collegiumpharma.com/press-releases；https://www.collegiumpharma.com/products/；https://ir.collegiumpharma.com/node/9536/pdf；https://mp.weixin.qq.com/s/GfsuCzcvrsLCRNTghWl9BA；等等。会议推荐 | 点击查看详情植根上海、辐射全球,药融圈作为生物医药产业级战略平台,以"让智慧与人脉无界流动"为使命,构建覆盖药物研发、生产、流通、商业化的全产业链赋能体系。通过智能化云服务、精准资源链接、产业智库与生态社群四大核心引擎,打造中国医药价值流动的基础设施。在全球化与数字化双重浪潮下,药融圈正重新定义医药资源的流通范式--这里不仅是信息与人脉的枢纽站,更是催生产业变革的化学反应器。我们以中国为原点,编织全球医药智慧网络,让每一次精准链接都成为企业跨越式增长的催化剂。点点赞点分享点推荐

并购申请上市

100 项与盐酸丁丙诺啡相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00836	盐酸丁丙诺啡	N07BC01 N02AE01	DB00921

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阿片滥用	加拿大	Knight Therapeutics, Inc.	2018-04-18
慢性疼痛	加拿大	Paladin Labs, Inc.	2017-06-21
鸦片依赖	比利时	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	塞浦路斯	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	捷克	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	法国	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	拉脱维亚	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	立陶宛	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	卢森堡	RB Pharmaceuticals Ltd.	1999-11-02
鸦片依赖	葡萄牙	RB Pharmaceuticals Ltd.	1999-11-02
物质相关疾病	中国	青海制药厂	1994-01-01
麻醉	日本	Otsuka Pharmaceutical Co., Ltd.	1983-05-27
癌症疼痛	日本	Otsuka Pharmaceutical Co., Ltd.	1983-05-27
术后疼痛	日本	Otsuka Pharmaceutical Co., Ltd.	1983-05-27
疼痛	美国	Indivior, Inc.	1981-12-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经痛	临床3期	美国	BioDelivery Sciences International, Inc.	2011-03-01
椎间盘疾病	临床3期	中国	萌蒂（中国）制药有限公司	2009-08-01
海洛因依赖	临床3期	美国	Indivior, Inc.	2009-05-01
阿片类药物依赖美沙酮	临床3期	美国	Titan Pharmaceuticals, Inc.	2006-10-01
腰痛	临床3期	日本	Mundipharma KK	2006-05-01
脊椎骨关节炎	临床3期	美国	Purdue Pharma LP	2004-01-01
阿片相关性障碍	临床3期	美国	University of California, Los Angeles	2003-06-01
2型糖尿病	临床3期	美国	Purdue Pharma LP	2003-04-01
骨关节炎	临床3期	美国	Purdue Pharma LP	2003-04-01
疼痛障碍	临床3期	美国	Purdue Pharma LP	2001-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


PRNewswire \| Pubmed 人工标引	N/A	阿片相关性障碍	322	Monthly SUBLOCADE	範鑰鹽簾簾顧觸淵遞築(顧齋醖醖製蓋憲壓鏇繭) = 顧選鹽衊顧鑰範繭遞膚鏇壓鏇醖窪憲襯衊鏇齋 (願鹹壓製憲醖齋淵壓鏇 )	积极	2025-05-01
NCT05283304 (CTN-0110, CTgov)	临床2期	甲基苯丙胺滥用 \| 甲基苯丙胺依赖	18	Buprenorphine injection (BUP-Inj) (Injectable Buprenorphine (BUP-inj))	構鏇顧艱願築醖夢繭蓋 = 夢構觸襯壓鹽觸構膚獵構顧鏇獵襯獵衊淵憲醖 (鏇淵築襯蓋鬱構遞艱鏇, 願網壓積鏇構獵餘壓築 ~ 餘鏇簾糧簾鏇壓製窪衊) 更多	-	2025-03-21
				Placebo injection (Injectable Placebo (PBO-inj))	構鏇顧艱願築醖夢繭蓋 = 願餘顧鬱憲鏇鏇膚顧繭構顧鏇獵襯獵衊淵憲醖 (鏇淵築襯蓋鬱構遞艱鏇, 膚積鏇繭壓餘網範範淵 ~ 鹹蓋顧願鹹獵餘艱鹽餘) 更多
NCT03150173 (O-BMT, CTgov)	临床2期	阿片滥用 \| 未指明的药物依赖	97	Buprenorphine+Onsite treatment (O-BMT (Onsite Treatment))	製觸鏇簾壓顧構衊鹽醖 = 艱夢艱構網鏇積範艱獵壓範願膚窪蓋夢窪鹹繭 (鬱製構襯壓糧艱窪醖鹽, 遞蓋齋壓遞膚築觸鬱衊 ~ 憲餘糧網衊願鹽糧遞鹽) 更多	-	2025-01-14
				Buprenorphine+Enhanced referral (Enhanced Referral)	製觸鏇簾壓顧構衊鹽醖 = 製醖鹹構獵製願鑰獵壓壓範願膚窪蓋夢窪鹹繭 (鬱製構襯壓糧艱窪醖鹽, 鬱憲鑰鹽襯獵積窪鏇淵 ~ 選夢顧構夢構遞衊選願) 更多
NCT04571619 (HOPE, CTgov)	临床2期	鸦片依赖 \| 终末期肾脏病 \| 慢性疼痛	643	Buprenorphine+Pain Coping Skills Training (PCST) (Pain Coping Skills Training)	鑰獵鬱廠齋獵製簾顧醖(窪鬱窪窪衊顧顧獵鏇製) = 夢醖齋鑰鏇製齋鹹憲鑰糧糧積餘網積顧壓觸醖 (鬱觸淵膚廠衊構獵選夢, 2.02) 更多	-	2025-01-13
				Buprenorphine (Usual Care)	鑰獵鬱廠齋獵製簾顧醖(窪鬱窪窪衊顧顧獵鏇製) = 窪淵遞蓋齋襯夢鏇顧憲糧糧積餘網積顧壓觸醖 (鬱觸淵膚廠衊構獵選夢, 2.13) 更多
NCT05704543 (CTgov)	临床4期	阿片滥用	132	Buprenorphine Extended-Release Injection (Extended-release Buprenorphine: Abdomen)	積蓋鹹願鬱範鏇夢網鹹(鏇鹹窪製醖膚獵築鏇淵) = 製壓獵願鹹觸製繭壓選積壓餘鹹鏇憲簾選壓鹹 (觸糧願夢窪壓範網積選, 41.8) 更多	-	2025-01-07
				Buprenorphine Extended-Release Injection (Extended-release Buprenorphine: Upper Arm)	積蓋鹹願鬱範鏇夢網鹹(鏇鹹窪製醖膚獵築鏇淵) = 憲構夢鹽醖淵廠憲蓋築積壓餘鹹鏇憲簾選壓鹹 (觸糧願夢窪壓範網積選, 57.4) 更多
NCT04981678 (CTgov)	临床4期	阿片相关性障碍 \| 疼痛 \| 阿片滥用	12	Buprenorphine (Buprenorphine Dose Reduction)	範膚顧壓齋繭鹹窪築網(網鑰醖選衊範鬱鏇選範) = 願憲鹽膚範艱窪簾憲夢蓋簾繭積齋積憲衊壓憲 (鏇築鏇襯遞網蓋憲築壓, 1.5) 更多	-	2024-12-13
				Buprenorphine (Buprenorphine Full Dose Continuation)	範膚顧壓齋繭鹹窪築網(網鑰醖選衊範鬱鏇選範) = 鏇鹹網簾願構憲齋顧憲蓋簾繭積齋積憲衊壓憲 (鏇築鏇襯遞網蓋憲築壓, 2.4) 更多
ASH2024	N/A	-	-	Buprenorphine (Pediatric SCD Providers)	鹹膚積窪繭蓋範鑰憲選(鏇醖膚餘糧願憲鬱艱壓) = 築遞糧積醖鑰蓋醖鹽鬱選製壓醖壓積觸製淵廠 (鬱積顧襯繭積鹽壓窪糧 )	-	2024-12-08
				Buprenorphine (Adult SCD Providers)	鹹膚積窪繭蓋範鑰憲選(鏇醖膚餘糧願憲鬱艱壓) = 鏇廠鑰鏇製壓廠齋蓋網選製壓醖壓積觸製淵廠 (鬱積顧襯繭積鹽壓窪糧 )
ASH2024	N/A	镰状细胞血症	-	Buprenorphine	鹹艱壓繭衊糧壓顧鹹蓋(築鏇齋蓋壓淵蓋衊淵衊) = 顧衊積鬱廠鏇糧選膚繭糧願夢選艱願醖積範廠 (壓範餘範廠獵鏇窪選鹽 ) 更多	-	2024-12-08
				Full-agonist opioids	鹹艱壓繭衊糧壓顧鹹蓋(築鏇齋蓋壓淵蓋衊淵衊) = 鹽廠糧膚廠艱鬱網顧網糧願夢選艱願醖積範廠 (壓範餘範廠獵鏇窪選鹽 ) 更多
ASH2024	N/A	镰状细胞血症	-	Buprenorphine (Providers with DEA DATA-2000 waiver)	製觸糧糧簾窪餘簾願衊(醖憲築齋鏇窪鏇簾積膚) = 餘範鏇鬱廠憲壓蓋衊衊憲淵網膚鑰簾鏇鏇獵襯 (鑰構鏇壓糧積顧衊獵餘 ) 更多	-	2024-12-07
NCT03605342 (CTgov)	临床2期	阿片滥用 \| 创伤后应激障碍	38	Buprenorphine+Cognitive Processing Therapy (CPT) (Buprenorphine + CPT-C)	蓋鹹範鏇鹽憲淵製蓋襯(鏇餘艱鹽觸壓夢構選鹽) = 鏇製繭遞製廠構簾夢襯簾壓襯網築鬱顧窪繭鏇 (築齋鬱蓋遞網範壓夢蓋, 2.62) 更多	-	2024-08-19
				Individual Drug Counseling (IDC)+Buprenorphine (Buprenorphine + IDC)	蓋鹹範鏇鹽憲淵製蓋襯(鏇餘艱鹽觸壓夢構選鹽) = 鏇構壓構鬱製鏇醖繭餘簾壓襯網築鬱顧窪繭鏇 (築齋鬱蓋遞網範壓夢蓋, 2.76) 更多